NHS can now prescribe Wegovy® as part of “controlled and limited” launch

Wegovy® can now be prescribed to individuals living with, or at risk of, type 2 diabetes, as part of a controlled and limited launch.

Novo Nordisk has announced that the weight-loss injection is now available in the UK despite their being a global shortage of the drug.

Accessible obesity care where there is high unmet medical need is at the forefront of the Government’s ambitions.

The launch of Wegovy® will help provide an additional option to support people living with obesity in the UK and healthcare providers are now one step closer to achieving this.

It is now available in specialist NHS weight management services for people who meet the National Institute for Care and Excellence (NICE) criteria2 or privately through a registered healthcare professional.

Through the specialist NHS services, people will also receive support with diet and exercise measures to follow by a multidisciplinary team.

As supply is expected to be constrained for the foreseeable future, a proportion of available supply will be allocated for use only within the NHS to allow healthcare professionals to implement NICE guidance.

The demand of Wegovy® is being closely watched by Novo Nordisk.